<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="Darifenacin" content-type="chapter" from-where="body" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">livertox</book-id>
    <book-title-group>
      <book-title>LiverTox</book-title>
      <subtitle>Clinical and Research Information on Drug-Induced Liver Injury</subtitle>
    </book-title-group>
    <pub-date date-type="pubr" publication-format="electronic">
      <year>2012</year>
    </pub-date>
    <publisher>
      <publisher-name>National Institute of Diabetes and Digestive and Kidney Diseases</publisher-name>
      <publisher-loc>Bethesda (MD)</publisher-loc>
    </publisher>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <book-part-id book-part-id-type="pmcid">Darifenacin</book-part-id>
      <title-group>
        <title>Darifenacin</title>
      </title-group>
      <pub-history>
        <date date-type="updated">
          <day>12</day>
          <month>7</month>
          <year>2023</year>
        </date>
      </pub-history>
      <related-object link-type="parent-book-link" source-id="livertox">LiverTox: Clinical and Research Information on Drug-Induced Liver Injury</related-object>
      <related-object link-type="previous-part-link" source-id="livertox" document-id="Daridorexant" document-type="chapter">Daridorexant</related-object>
      <related-object link-type="next-part-link" source-id="livertox" document-id="Darolutamide" document-type="chapter">Darolutamide</related-object>
    </book-part-meta>
    <body>
      <sec id="Darifenacin.OVERVIEW">
        <title>OVERVIEW</title>
        <sec id="Darifenacin.Introduction" sec-type="pubmed-excerpt">
          <title>Introduction</title>
          <p>Darifenacin is an anticholinergic and antispasmotic agent used to treat urinary incontinence and overactive bladder syndrome. Darifenacin has not been implicated in causing liver enzyme elevations or clinically apparent acute liver injury.</p>
        </sec>
        <sec id="Darifenacin.Background">
          <title>Background</title>
          <p>Darifenacin (dar" i fen' a sin) is an anticholinergic agent with a degree of selectivity for the M3 subtype of muscarinic acetylcholine receptors which are found predominantly in the smooth muscle of the bladder. Darifenacin increases bladder capacity and decreases bladder contractions and the urgency of urination. Darifenacin was approved for use in the United States in 2004 and indications include urinary urge incontinence and overactive bladder syndrome. Darifenacin is available in extended release tablets of 7.5 and 15 mg generically and under the brand name Enablex. The recommended adult oral dose is 7.5 to 15 mg once daily. Common side effects are those of parasympathetic stimulation and include dryness of the mouth and eyes, decreased sweating, headache, visual blurring, constipation, and urinary retention. Because of its selectivity for the M3 muscarinic receptor, darifenacin is believed to be less likely than other anticholinergic agents to cause central nervous system effects such as restlessness, confusion and hallucinations. Rare but potentially severe adverse reactions include acute narrow angle glaucoma, acute urinary retention, and severe hypersensitivity reactions.</p>
        </sec>
        <sec id="Darifenacin.Hepatotoxicity">
          <title>Hepatotoxicity</title>
          <p>Like most anticholinergic agents, darifenacin has not been linked to liver enzyme elevations during therapy or to instances of clinically apparent liver injury with symptoms or jaundice. In multiple prospective clinical trial of darifenacin in patients with overactive bladder syndrome, ALT elevations were reported in less than 1% of treated subjects, rates similar to that of placebo recipients. Despite widespread clinical use for almost two decades, there have been no published case reports of clinically apparent liver injury convincingly attributed to darifenacin use.</p>
          <p>Likelihood score: E (unlikely cause of clinically apparent liver injury).</p>
        </sec>
        <sec id="Darifenacin.Mechanism_of_Injury">
          <title>Mechanism of Injury</title>
          <p>Darifenacin has not been linked to liver injury. It is metabolized in the liver by microsomal P450 enzymes, predominantly CYP 3A4 and 2D6. Despite this, drug-drug interactions are uncommon. A major reason for its safety may relate to the low daily dose.</p>
          <p>Drug Class: <related-object link-type="booklink" source-id="livertox" document-id="Anticholinergics" document-type="chapter">Anticholinergic Agents</related-object></p>
        </sec>
      </sec>
      <sec id="Darifenacin.PRODUCT_INFORMATION">
        <title>PRODUCT INFORMATION</title>
        <p>
<bold>REPRESENTATIVE TRADE NAMES</bold>
</p>
        <p>Darifenacin &#x02013; Generic, Enablex&#x000ae;</p>
        <p>
<bold>DRUG CLASS</bold>
</p>
        <p>Anticholinergic Agents</p>
        <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&#x00026;query=Darifenacin">COMPLETE LABELING</ext-link>
</p>
        <p>Product labeling at DailyMed, National Library of Medicine, NIH</p>
      </sec>
      <sec id="Darifenacin.CHEMICAL_FORMULA_AND_STRUCTU">
        <title>CHEMICAL FORMULA AND STRUCTURE</title>
        <table-wrap id="Darifenacin.Tc" orientation="portrait" position="anchor">
          <table frame="hsides" rules="groups">
            <thead>
              <tr>
                <th id="hd_h_Darifenacin.Tc_1_1_1_1" valign="top" align="left" scope="col" rowspan="1" colspan="1">DRUG</th>
                <th id="hd_h_Darifenacin.Tc_1_1_1_2" valign="top" align="left" scope="col" rowspan="1" colspan="1">CAS REGISTRY NUMBER</th>
                <th id="hd_h_Darifenacin.Tc_1_1_1_3" valign="top" align="left" scope="col" rowspan="1" colspan="1">MOLECULAR FORMULA</th>
                <th id="hd_h_Darifenacin.Tc_1_1_1_4" valign="top" align="left" scope="col" rowspan="1" colspan="1">STRUCTURE</th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td headers="hd_h_Darifenacin.Tc_1_1_1_1" valign="top" align="left" scope="row" rowspan="1" colspan="1">Darifenacin</td>
                <td headers="hd_h_Darifenacin.Tc_1_1_1_2" valign="top" align="left" rowspan="1" colspan="1">
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pubchem" xlink:href="sid://135030473">133099-04-4</ext-link>
</td>
                <td headers="hd_h_Darifenacin.Tc_1_1_1_3" valign="top" align="left" rowspan="1" colspan="1">C28-H30-N2-O2</td>
                <td headers="hd_h_Darifenacin.Tc_1_1_1_4" valign="top" align="left" rowspan="1" colspan="1">
<related-object link-type="ext-image-back-link" source-id="pubchem" document-id="135030473" document-id-type="sid" document-type="summary" object-id="135030473" object-id-type="sid" object-type="image"/>
</td>
              </tr>
            </tbody>
          </table>
        </table-wrap>
      </sec>
      <sec id="Darifenacin.ANNOTATED_BIBLIOGRAPHY">
        <title>ANNOTATED BIBLIOGRAPHY</title>
        <p>References updated: 12 July 2023</p>
        <p>Abbreviations: ER, extended release.</p>
        <ref-list id="Darifenacin.ANNOTATED_BIBLIOGRAPHY.reflist0">
          <ref id="Darifenacin.REF.zimmerman.1999">
            <mixed-citation publication-type="book">Zimmerman HJ. Hepatotoxicity: the adverse effects of drugs and other chemicals on the liver. 2nd ed. Philadelphia: Lippincott, 1999.<annotation><p><italic toggle="yes">(Expert review of hepatotoxicity published in 1999 before the availability of darifenacin and other therapies of overactive bladder syndrome).</italic></p></annotation></mixed-citation>
          </ref>
          <ref id="Darifenacin.REF.brown.2018">
            <mixed-citation publication-type="book">Brown JH, Brandl K, Wess J. Therapeutic uses of muscarinic receptor antagonists: Muscarinic receptor agonists and antagonists. In, Brunton LL, Hilal-Dandan R, Knollman BC, eds. Goodman &#x00026; Gilman&#x02019;s the pharmacological basis of therapeutics. 13th ed. New York: McGraw-Hill, 2018, pp. 156-9.<annotation><p><italic toggle="yes">(Textbook of pharmacology and therapeutics).</italic></p></annotation></mixed-citation>
          </ref>
          <ref id="Darifenacin.REF.chapple.2005.993">
            <mixed-citation publication-type="journal"><string-name name-style="western"><surname>Chapple</surname>
<given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Steers</surname>
<given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Norton</surname>
<given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Millard</surname>
<given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Kralidis</surname>
<given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Glavind</surname>
<given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Abrams</surname>
<given-names>P.</given-names></string-name>
<article-title>A pooled analysis of three phase III studies to investigate the efficacy, tolerability and safety of darifenacin, a muscarinic M3 selective receptor antagonist, in the treatment of overactive bladder.</article-title>
<source>BJU Int.</source>
<year>2005</year>;<volume>95</volume>:<fpage>993</fpage>-<lpage>1001</lpage>.<annotation><p><italic toggle="yes">(Among 1059 adults with symptomatic overactive bladder treated with darifenacin [7.5 or 15 mg] or placebo once daily for 12 weeks in 3 controlled trials, darifenacin resulted in significant decreases in episodes of incontinence, urgency and daily micturitions compared to placebo, while adverse events arose in 54% and 66% vs 49%, the most common symptoms being dry mouth and constipation, but &#x0201c;there were no concerns from laboratory data&#x0201d;).</italic></p></annotation><pub-id pub-id-type="pmid">15839920</pub-id>
</mixed-citation>
          </ref>
          <ref id="Darifenacin.REF.zinner.2005.248">
            <mixed-citation publication-type="journal"><string-name name-style="western"><surname>Zinner</surname>
<given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Tuttle</surname>
<given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Marks</surname>
<given-names>L</given-names></string-name>. <article-title>Efficacy and tolerability of darifenacin, a muscarinic M3 selective receptor antagonist (M3 SRA), compared with oxybutynin in the treatment of patients with overactive bladder.</article-title>
<source>World J Urol</source>
<year>2005</year>; <volume>23</volume>: <fpage>248</fpage>-<lpage>52</lpage>.<annotation><p><italic toggle="yes">(Trial comparing darifenacin with oxybutynin in 76 patients with overactive bladder found similar rates of response but less dry mouth with darifenacin: no mention of hepatotoxicity or ALT elevations).</italic></p></annotation><pub-id pub-id-type="pmid">16096831</pub-id>
</mixed-citation>
          </ref>
          <ref id="Darifenacin.REF.novara.2008.740">
            <mixed-citation publication-type="journal"><string-name name-style="western"><surname>Novara</surname>
<given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Galfano</surname>
<given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Secco</surname>
<given-names>S</given-names></string-name>, <string-name name-style="western"><surname>D'Elia</surname>
<given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Cavalleri</surname>
<given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Ficarra</surname>
<given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Artibani</surname>
<given-names>W.</given-names></string-name>
<article-title>A systematic review and meta-analysis of randomized controlled trials with antimuscarinic drugs for overactive bladder.</article-title>
<source>Eur Urol</source>
<year>2008</year>; <volume>54</volume>: <fpage>740</fpage>-<lpage>63</lpage>.<annotation><p><italic toggle="yes">(Systematic review of efficacy and safety of drugs for overactive bladder including tolterodine, propiverine, solifenacin, darifenacin, fesoterodine and oxybutynin; common side effects included dry mouth and constipation; hepatotoxicity and ALT elevations were not mentioned).</italic></p></annotation><pub-id pub-id-type="pmid">18632201</pub-id>
</mixed-citation>
          </ref>
          <ref id="Darifenacin.REF.chalasani.2008.1924">
            <mixed-citation publication-type="journal"><string-name name-style="western"><surname>Chalasani</surname>
<given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Fontana</surname>
<given-names>RJ</given-names></string-name>, <string-name name-style="western"><surname>Bonkovsky</surname>
<given-names>HL</given-names></string-name>, <string-name name-style="western"><surname>Watkins</surname>
<given-names>PB</given-names></string-name>, <string-name name-style="western"><surname>Davern</surname>
<given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Serrano</surname>
<given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Yang</surname>
<given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Rochon</surname>
<given-names>J</given-names></string-name>; <collab>Drug Induced Liver Injury Network (DILIN)</collab>. <article-title>Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States.</article-title>
<source>Gastroenterology</source>
<year>2008</year>; <volume>135</volume>: <fpage>1924</fpage>-<lpage>34</lpage>.<annotation><p><italic toggle="yes">(Among 300 cases of drug induced liver disease in the US collected between 2004 and 2008, none were attributed to anticholinergics or drugs for overactive bladder).</italic></p></annotation><pub-id pub-id-type="pmid">18955056</pub-id>
</mixed-citation>
          </ref>
          <ref id="Darifenacin.REF.reuben.2010.2065">
            <mixed-citation publication-type="journal"><string-name name-style="western"><surname>Reuben</surname>
<given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Koch</surname>
<given-names>DG</given-names></string-name>, <string-name name-style="western"><surname>Lee</surname>
<given-names>WM</given-names></string-name>; <collab>Acute Liver Failure Study Group</collab>. <article-title>Drug-induced acute liver failure: results of a U.S. multicenter, prospective study.</article-title>
<source>Hepatology</source>
<year>2010</year>; <volume>52</volume>: <fpage>2065</fpage>-<lpage>76</lpage>.<annotation><p><italic toggle="yes">(Among 1198 patients with acute liver failure enrolled in a US prospective study between 1998 and 2007, 133 were attributed to drug induced liver injury, but none were attributed to anticholinergics or drugs for overactive bladder syndrome).</italic></p></annotation><pub-id pub-id-type="pmid">20949552</pub-id>
</mixed-citation>
          </ref>
          <ref id="Darifenacin.REF.ferrajolo.2010.721">
            <mixed-citation publication-type="journal"><string-name name-style="western"><surname>Ferrajolo</surname>
<given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Capuano</surname>
<given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Verhamme</surname>
<given-names>KM</given-names></string-name>, <string-name name-style="western"><surname>Schuemie</surname>
<given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Rossi</surname>
<given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Stricker</surname>
<given-names>BH</given-names></string-name>, <string-name name-style="western"><surname>Sturkenboom</surname>
<given-names>MC</given-names></string-name>. <article-title>Drug-induced hepatic injury in children: a case/non-case study of suspected adverse drug reactions in VigiBase.</article-title>
<source>Br J Clin Pharmacol</source>
<year>2010</year>; <volume>70</volume>: <fpage>721</fpage>-<lpage>8</lpage>.<annotation><p><italic toggle="yes">(Among 624,673 adverse event reports in children between 2000 and 2006 in the WHO VigiBase, 1% were hepatic, but no anticholinergic was listed among the 41 most frequently implicated agents).</italic></p></annotation><pub-id pub-id-type="pmid">21039766</pub-id>
</mixed-citation>
          </ref>
          <ref id="Darifenacin.REF.bj_rnsson.2013.1419">
            <mixed-citation publication-type="journal"><string-name name-style="western"><surname>Bj&#x000f6;rnsson</surname>
<given-names>ES</given-names></string-name>, <string-name name-style="western"><surname>Bergmann</surname>
<given-names>OM</given-names></string-name>, <string-name name-style="western"><surname>Bj&#x000f6;rnsson</surname>
<given-names>HK</given-names></string-name>, <string-name name-style="western"><surname>Kvaran</surname>
<given-names>RB</given-names></string-name>, <string-name name-style="western"><surname>Olafsson</surname>
<given-names>S</given-names></string-name>. <article-title>Incidence, presentation and outcomes in patients with drug-induced liver injury in the general population of Iceland.</article-title>
<source>Gastroenterology</source>
<year>2013</year>; <volume>144</volume>: <fpage>1419</fpage>-<lpage>25</lpage>.<annotation><p><italic toggle="yes">(In a population based study of drug induced liver injury from Iceland, 96 cases were identified over a 2 year period, but none were attributed to mirabegron or drugs for overactive bladder syndrome).</italic></p></annotation><pub-id pub-id-type="pmid">23419359</pub-id>
</mixed-citation>
          </ref>
          <ref id="Darifenacin.REF.hern_ndez.2014.231">
            <mixed-citation publication-type="journal"><string-name name-style="western"><surname>Hern&#x000e1;ndez</surname>
<given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Bessone</surname>
<given-names>F</given-names></string-name>, <string-name name-style="western"><surname>S&#x000e1;nchez</surname>
<given-names>A</given-names></string-name>, <string-name name-style="western"><surname>di Pace</surname>
<given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Brahm</surname>
<given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Zapata</surname>
<given-names>R, A</given-names></string-name>
<string-name name-style="western"><surname>Chirino</surname>
<given-names>R</given-names></string-name>, <etal>et al.</etal>
<article-title>Profile of idiosyncratic drug induced liver injury in Latin America. An analysis of published reports.</article-title>
<source>Ann Hepatol</source>
<year>2014</year>; <volume>13</volume>: <fpage>231</fpage>-<lpage>9</lpage>.<annotation><p><italic toggle="yes">(Systematic review of literature of drug induced liver injury in Latin American countries published from 1996 to 2012 identified 176 cases, but none were attributed to drugs used for overactive bladder syndrome).</italic></p></annotation><pub-id pub-id-type="pmid">24552865</pub-id>
</mixed-citation>
          </ref>
          <ref id="Darifenacin.REF.chalasani.2015.1340">
            <mixed-citation publication-type="journal"><string-name name-style="western"><surname>Chalasani</surname>
<given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Bonkovsky</surname>
<given-names>HL</given-names></string-name>, <string-name name-style="western"><surname>Fontana</surname>
<given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Lee</surname>
<given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Stolz</surname>
<given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Talwalkar</surname>
<given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Reddy</surname>
<given-names>KR</given-names></string-name>, <etal>et al.</etal>; <collab>United States Drug Induced Liver Injury Network</collab>. <article-title>Features and outcomes of 899 patients with drug-induced liver injury: the DILIN Prospective Study.</article-title>
<source>Gastroenterology</source>
<year>2015</year>; <volume>148</volume>: <fpage>1340</fpage>-<lpage>1352.e7</lpage>.<annotation><p><italic toggle="yes">(Among 899 cases of drug induced liver injury enrolled in a US prospective study between 2004 and 2013, none were attributed to mirabegron or other agents for overactive bladder syndrome).</italic></p></annotation><pub-id pub-id-type="pmid">25754159</pub-id>
</mixed-citation>
          </ref>
          <ref id="Darifenacin.REF12">
            <mixed-citation publication-type="journal"><article-title>Drugs for overactive bladder.</article-title>
<source>Med Lett Drugs Ther.</source>
<year>2023</year>;<volume>65</volume>:<fpage>41</fpage>-<lpage>45</lpage>.<annotation><p><italic toggle="yes">(Concise review of drugs approved for therapy of overactive bladder in the US including anticholinergic agents [darifenacin, fesoterodine, oxbutynin, solifenacin, tolterodine and trospium] and beta-3 adrenergic receptor agonists [mirabegron and vibegron], including clinical efficacy, safety, and costs; no mention of ALT elevations or hepatotoxicity of any of the agent discussed).</italic></p></annotation><pub-id pub-id-type="pmid">36897601</pub-id>
</mixed-citation>
          </ref>
        </ref-list>
      </sec>
      <sec sec-type="link-group" id="Darifenacin.OTHER_REFERENCE_LINKS">
        <title>OTHER REFERENCE LINKS</title>
        <list list-type="order">
          <list-item>
            <label>1</label>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&#x00026;db=pubmed&#x00026;pubmedfilters=true&#x00026;term=(Darifenacin/AE)+AND+Human%5BMH%5D+AND+(drug+induced+liver+injury+OR+jaundice/CI+OR+bile+duct+diseases/CI+OR+liver/DE+OR+liver+diseases/CI)+AND+(%221900/1/1%22%5BEDat%5D:%222999/12/31%22%5BEDat%5D)">Recent References on Darifenacin: from PubMed.gov</ext-link>
</p>
          </list-item>
          <list-item>
            <label>2</label>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/results?term=Darifenacin">Trials on Darifenacin: from ClinicalTrials.gov</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
  </book-part>
</book-part-wrapper>
